BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 26
• 27
• 28
• 29

• Drug Development

  Alexion Pharmaceuticals Inc. Eculizumab Is Well Tolerated And Demonstrates Significant Improvement During 52 Weeks Of Treatment In Open-Label Phase III SHEPHERD Study In PNH Patients

  December 11, 2006

   · 

  10 min read
• Pharm Country

  NanoViricides, Inc.'s President Chosen As Special Lecturer At Nanotechnology Conference - Biomedical Applications Attended By Leading Government And Industry Scientists

  December 11, 2006

   · 

  1 min read
• Business

  ViroPharma Incorporated Chooses MediData Solutions As Its Standard For Global Clinical Trials Management

  December 11, 2006

   · 

  1 min read
• Drug Development

  Gemin X Biotechnologies Inc. Phase 1 Data Show Clinical Activity Of GX15-070 In Myelodysplastic Syndromes

  December 11, 2006

   · 

  1 min read
• Business

  Beijing Med-Pharm Corp. Enters Into An Agreement To Develop And Register Products For Cephalon, Inc. In China

  December 11, 2006

   · 

  1 min read
• Drug Development

  Merck & Co., Inc. And Vertex Pharmaceuticals Incorporated Announce Phase I Results For Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity In Patients With Treatment- Resistant Forms Of Advanced Leukemias And Myeloproliferat

  December 11, 2006

   · 

  1 min read
• Drug Development

  Phase I/II Data Support Continued Development Of Biogen Idec, Inc. (Massachusetts)'s Novel Anti-CD23 Antibody For Chronic Lymphocytic Leukemia

  December 11, 2006

   · 

  1 min read
• Bioenvision Announces Latest Data On Evoltra(R) In Pediatric And Adult Leukemias

  December 11, 2006

   · 

  1 min read
• Biotech Beach

  The Immune Response Corporation, Inc. Announces That Previously Approved One-for-100 Reverse Stock Split Will Take Effect On December 20, 2006

  December 11, 2006

   · 

  1 min read
• Drug Development

  GlaxoSmithKline Release: Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes And Improved Platelet Counts In Patients With Chronic Idiopathic Thrombocytopenic Purpura

  December 11, 2006

   · 

  7 min read